Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-28
84
Participants Needed
285
Research Sites
N/A
Total Duration
This trial focuses on patients with CD22-positive B-lineage acute lymphoblastic leukemia ALL that is newly diagnosed, has returned after improvement, or does not respond to treatment. Researchers are studying how well the combination of inotuzumab ozogamicin and blinatumomab, with or without ponatinib, works in treating this type of leukemia. The study aims to confirm tolerability and estimate survival and response rates in different patient groups, including those with Philadelphia chromosome-negative and positive disease. Participants are assigned to one of three groups. Cohorts 1 and 2 receive inotuzumab ozogamicin intravenously on specific days, followed by blinatumomab infusions over several weeks. Cohort 3 receives a combination of ponatinib pills daily, intravenous inotuzumab ozogamicin, blinatumomab infusions, dexamethasone, methotrexate injections into the spine, and may receive allogeneic hematopoietic cell transplantation based on response. Treatment courses vary in length from 21 days to 126 days, followed by a maintenance phase with ponatinib lasting up to 24 months. Throughout the study, participants undergo bone marrow aspiration and biopsy, blood and cerebrospinal fluid sample collection, and lumbar punctures. Researchers monitor event-free survival, overall survival, relapse-free survival, response rates, molecular responses, and treatment safety for up to 10 years. After completing treatment, patients have follow-up visits every 3 months for 3 years, then every 6 months for up to 10 years to assess long-term outcomes and side effects.
CONDITIONS
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational regimen | Current standard‑of‑care regimens |
|---|---|---|
| What it is | Combination of inotuzumab ozogamicin and blinatumomab, with addition of ponatinib in cohort 3 as investigational therapy in B‑cell ALL | Multiagent chemotherapy regimens (eg, Hyper‑CVD or pediatric‑inspired backbones) sometimes combined with inotuzumab or blinatumomab per current ALL management practice |
| Role in trial | Investigational intervention assigned in three separate cohorts based on age, prior therapy, and Philadelphia chromosome status | Not studied within this trial, serves as external comparator for context |
| Primary use | Being evaluated as first-line or salvage therapy for CD22‑positive B‑ALL depending on cohort | Currently used as frontline or salvage treatment in Ph‑negative B‑ALL, sometimes with immunotherapy components |
| How it is given or performed | InO and blinatumomab are administered per protocol, with IV dosing and addition of oral ponatinib for cohort 3 | Typically involves multiagent chemotherapy delivered intravenously over cycles, with some protocols adding inotuzumab or blinatumomab |
| Evidence status | Efficacy under evaluation in this trial; preliminary external data support use of InO and blinatumomab in similar patients | Established survival benefit when chemotherapy is combined with immunotherapy in Ph‑negative B‑ALL |
| Important risks | Potential risks include those associated with InO, Blina, and ponatinib but trial‑specific safety data not yet available | Known risks include chemotherapy toxicity and immunotherapy‑related adverse effects, such as hepatotoxicity with InO and neurologic events with Blina |
| Important limitations | Non‑randomized design limits direct efficacy comparison; inclusion of different cohorts may affect generalizability | Standard regimens vary widely and may not include newer targeted agents uniformly; toxicity remains a concern in older adults |
| Patient impact | Unknown; patient‑relevant outcomes are being assessed in the trial | Chemotherapy plus immunotherapy is associated with improved survival and remission rates in Ph‑negative B‑ALL |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 24 months
Participants receive assigned treatments, including intravenous inotuzumab ozogamicin and blinatumomab, oral ponatinib for some, dexamethasone, and methotrexate injections, depending on their cohort. Treatment courses vary in length with careful monitoring for response and side effects.
Multiple visits for infusions, oral medication administration, and assessments
Duration - Up to 10 years
After completing treatment, participants are followed with regular visits every 3 months for 3 years, then every 6 months for up to 10 years to monitor long-term outcomes and safety.
Visits every 3 to 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Zheng Shi, Yiqian Zhu, Jing Zhang...
https://pubmed.ncbi.nlm.nih.gov/35622074/Matthew J Wieduwilt, Jun Yin, Oudom Kour...
https://pubmed.ncbi.nlm.nih.gov/41026957/National Cancer Institute (NCI)
Lead Sponsor